Lumanity

Just released: The Medical Affairs Blueprint for Biotech Too many pre-revenue and early commercial biotechs treat medical affairs as a “later” build. In today’s environment, that’s a risky bet. Scientific complexity is rising, stakeholders expect differentiated evidence, and access to HCPs and payers is increasingly constrained. The result? A growing need for an earlier, credible, and non-promotional scientific exchange. This whitepaper is a blueprint for creating a lean, future-fit medical affairs function that delivers measurable value from day one. Download: https://buff.ly/sQMGa03 #MedicalAffairs #Biotech #CommercialStrategy #EvidenceGeneration

Most biotech companies know they need a medical affairs plan and then a medical affairs team to implement it. What is harder to see and appreciate, from inside a resource-constrained pipeline and regulatory approval-oriented effort, is exactly when that investment needs to begin. In the latest episode of Medical Affairs Unscripted, Peg Crowley-Nowick sits down with Nicholas Sarlis, MD, PhD, FACP, Chief Medical Officer at CLEARA Biotech, for one of the most practical conversations we have had on launch readiness in biotech. Nick has led six product launches across nine indications. He does not talk in theory. He talks in timelines, trade-offs, and hard-won decisions. In this episode you will hear: • Why T-minus 30 months is the new standard for medical affairs engagement, and why most biotechs are still starting to gear up too late • How to sequence your first three critical hires when budget is tight and pressure is high • Why a fractured scientific narrative across commercial, clinical, and corporate communications can damage your standing with the KOLs and investors you need most • What disciplined insight management actually looks like in a lean field medical team • How early patient advocacy engagement has shifted from optional to essential This is a conversation for medical affairs leaders, biotech CMOs, and anyone advising clinical-stage companies on what it takes to move from pivotal data delivery to a successful launch. Listen now: https://buff.ly/zaNdg6H #MedicalAffairs #MedicalAffairsUnscripted #Biotech #CMO #LaunchStrategies

Lumanity is proud to participate in Patients as Partners EU 2026! Earlier today Susan Daniels, SVP, Patient Strategy & Engagement at Lumanity moderated a truly engaging panel discussion, “Criteria for Patient Engagement Post Clinical Research Studies,” featuring panelists Bernard Chylinski, Cristian Perez Gomez, and Peter DiBiaso who shared their perspectives on how to continue involving patients after a trial ends. Thanks to everyone who connected with us at the conference! In case we missed you, reach out today to learn how we can up-level your patient strategy and engagement: https://buff.ly/2tVbJyg #PatientsEU2026 #PatientEngagement #PatientsAsPartners #LifeSciencesConsulting

That’s a wrap! Thank you to everyone who connected with us at #ISPORAnnual; as always it was great to speak to so many clients, colleagues and experts. Also, a huge thank you to all our #Lumanity colleagues who have worked so hard on the scientific content we showcased this year, and for representing us so well in Philadelphia! We hope to see you later this year at ISPOR Europe in Vienna. #OutcomesResearch #HEOR #HealthEconomics #HTA #RWE #PatientCenteredOutcomes

We're counting day to the ASCO annual meeting! If you're planning to be in Chicago for the meeting, let's connect and discuss how we can support your oncology initiatives and drive better patient outcomes. Reach out to contact@lumanity.com or one of our attendees directly to set up time to meet. Lumanity staff attending the meeting include Dennis Chang, Donna Arbitman, Ed Senior, Eleanor Johns, PhD, Eric Gustafson, Erin Kavanagh (Amato), Jackie Stone, Jane Ayton, Jeff Bockman, Keitel Suri, Ken Jordan, Michael Parisi, Michele Zheng, Migi Che (Lee), MS, BCMAS, Michael Rice, Natalie Thovmasian, Pamela Chiesi, Rob Rawlinson, Sean Parrett, Tyler McCullough, PhD, Tyler Nellos, and Viraj Parekh. Learn more about our Oncology expertise: https://buff.ly/z9RgW4Y #ASCO26 #CancerResearch #OncologyExpertise

In collaboration with Lareb, experts from the PHARMO Institute assessed whether COVID-19 vaccination in the Netherlands was followed by an uptick in GP consultations for venous thromboembolism (VTE)—blood clots in the veins. Leveraging GP data from PHARMO and Nivel covering more than 2.13 million vaccinated individuals, we observed the clearest increase after the Johnson & Johnson vaccine, a more modest rise following Pfizer/BioNTech dose 1, and generally no increase for Moderna or AstraZeneca across most groups. Overall, vector-based vaccines were associated with larger relative increases than mRNA vaccines. The signal was more pronounced in certain subpopulations, including males aged 12–60 and females using hormonal contraceptives or hormone replacement therapy (HRT). Although these events remain rare, the findings reinforce why continuous pharmacovigilance—and targeted follow-up research in potentially higher-risk groups—is so important. Read the full study via Pharmacoepidemiology & Drug Safety: https://buff.ly/kZsGmew

The message from Asembia’s #AXS26 was clear: intentionality in study design and early commercialization planning is foundational to access success. As specialty pharma faces rising payer scrutiny and growing complexity, success in the Artificial Intelligence (AI) era will depend on thinking upstream, acting earlier, and aligning smarter. We’ve captured key insights on: • Why access is becoming harder to secure • How AI is reshaping payer–manufacturer dynamics • What leading organizations are doing differently Read our reflections from Asembia to stay ahead of the access challenge: https://buff.ly/wJukRLF #ASX26 #MarketAccess #HEOR

We’re looking forward to another great day at #ISPORAnnual! If you’re attending, do pop into the Poster Hall and check out our latest research - we have five posters on display today! And while you’re making your way around, come and find us at booth #624. It’s a great chance to meet the team and have a chat. Find out more about Lumanity at this year’s ISPOR on our website: https://buff.ly/7UzqMiT #ISPORAnnual #OutcomesResearch #HEOR #HealthEconomics #HTA #RWE #PatientCenteredOutcomes

Launching a pharma product is a high-stakes, pressure-filled marathon where poor planning shows up too late to fix. In this episode, launch experts Andrew Mooney and Laurence Cooper unpack the complexity and pressure of pharma launches for first-time and small organizations. They outline the five fundamentals of success while emphasizing the need for focus and alignment and highlight the importance of early planning, critical path mapping, and honest KPIs to avoid surprises and deliver a confident launch. If you’re preparing for a first-time or early-stage pharma launch, this conversation breaks down exactly how to stay focused, avoid costly surprises, and execute with confidence! Listen: https://buff.ly/G1ZNENc

Thank you to everyone who stopped by our booth at MAPS EMEA in Zurich! It was a pleasure connecting with so many Medical Affairs leaders and teams focused on what is next for the function. If we did not get enough time together onsite, we would welcome a follow-up conversation to discuss your strategic priorities, and/or take a deeper dive into our unique platforms: • Expert Navigator, supporting expert-led KOL identification and mapping • Evidence Navigator Hub, designed to connect strategy to evidence gaps and tactics in one integrated place Send us a message to schedule a demo or continue the discussion: contact@lumanity.com